Immunotherapy in non-small cell lung cancer : shifting prognostic paradigms

Megan B. Barnet; Wendy A. Cooper; Michael J. Boyer; Steven Kao

doi:10.3390/jcm7060151

Immunotherapy in non-small cell lung cancer : shifting prognostic paradigms

Megan B. Barnet
, Wendy A. Cooper
, Michael J. Boyer
, Steven Kao

Western Sydney University

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where best-case scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice.

Original language	English
Article number	151
Number of pages	14
Journal	Journal of Clinical Medicine
Volume	7
Issue number	6
DOIs	https://doi.org/10.3390/jcm7060151
Publication status	Published - 2018

Open Access - Access Right Statement

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

cancer
immunotherapy
lungs

Access to Document

10.3390/jcm7060151

Cite this

@article{1de0f25ac4d94f1b85e2648342e0612d,

title = "Immunotherapy in non-small cell lung cancer : shifting prognostic paradigms",

abstract = "Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where best-case scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice.",

keywords = "cancer, immunotherapy, lungs",

author = "Barnet, \{Megan B.\} and Cooper, \{Wendy A.\} and Boyer, \{Michael J.\} and Steven Kao",

year = "2018",

doi = "10.3390/jcm7060151",

language = "English",

volume = "7",

journal = "Journal of Clinical Medicine",

issn = "2077-0383",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "6",

}

TY - JOUR

T1 - Immunotherapy in non-small cell lung cancer : shifting prognostic paradigms

AU - Barnet, Megan B.

AU - Cooper, Wendy A.

AU - Boyer, Michael J.

AU - Kao, Steven

PY - 2018

Y1 - 2018

N2 - Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where best-case scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice.

AB - Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where best-case scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice.

KW - cancer

KW - immunotherapy

KW - lungs

UR - http://handle.westernsydney.edu.au:8081/1959.7/uws:47924

U2 - 10.3390/jcm7060151

DO - 10.3390/jcm7060151

M3 - Article

SN - 2077-0383

VL - 7

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

IS - 6

M1 - 151

ER -

Immunotherapy in non-small cell lung cancer : shifting prognostic paradigms

Abstract

Open Access - Access Right Statement

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this